Skip to content

The Effect of Continuous Management of Suction Cuff Pressure and Subglottic Irrigation Suction on Preventing VALRI Study

The Effect of Continuous Management of Suction Cuff Pressure and Subglottic Irrigation Suction on the Outcomes of Mechanically Ventilated Patients With High Risk of Aspiration: a Single-center, Prospective, Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06867237
Acronym
SCOPE
Enrollment
90
Registered
2025-03-10
Start date
2025-03-01
Completion date
2026-12-31
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilation Acquired Pneumonia

Brief summary

Assessing the effectiveness of continuous cuff pressure management combined with subglottic suction irrigation in reducing ventilator-associated lower respiratory tract infections (VALRTI) in mechanically ventilated patients at high risk of aspiration.

Interventions

DEVICESuction cuff pressure

Use the device to do continuous management of suction cuff pressure and subglottic irrigation suction

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years; 2. Undergoing endotracheal intubation or tracheostomy; 3. Expected duration of mechanical ventilation exceeding 72 hours; 4. Presence of one or more high-risk factors for reflux/aspiration: recurrent laryngeal nerve injury, cerebral infarction/cerebral hemorrhage (new or pre-existing swallowing dysfunction), cranial surgery/traumatic brain injury (TBI), neuromuscular junction disorders (e.g., myasthenia gravis, muscular dystrophy, Parkinson's disease, or other conditions that weaken swallowing muscle strength and coordination), continuous use of muscle relaxants for ≥ 48 hours during mechanical ventilation, ICU-acquired myopathy, ICU-acquired weakness, gastroparesis (gastric residual volume \> 500 mL/6 hours), or impaired consciousness; 5. Voluntary participation in the study by the subject or their legal representative, with signed informed consent.

Exclusion criteria

1. Expected duration of mechanical ventilation less than 48 hours; 2. Pregnant or breastfeeding women; 3. Patients with tracheoesophageal or bronchopleural fistula; 4. Difficult intubation (more than three attempts) or patients with reflux/aspiration during intubation (with lung injury and secondary pulmonary infection); 5. Patients with irreversible disease, end-stage conditions, or those expected to die in the near future; 6. Patients already diagnosed with ventilator-associated pneumonia (VAP), i.e., excluding hospital-acquired pneumonia; 7. Patients participating in other clinical trials that are expected to influence the results of this study; 8. Patients deemed unsuitable for inclusion in the study by the investigator.

Design outcomes

Primary

MeasureTime frameDescription
The number of days free from VALRTI within 28 days.28 daysThe number of days free from ventilator-associated lower respiratory tract infection (VALRTI) within 28 days.

Contacts

Primary ContactYanni Zhang, dr.
zhang.yanni@zs-hospital.sh.cn13381819621

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026